title: 3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
authors.forename: U
authors.initials: U
authors.lastname: Creutzig
authors.forename: D
authors.initials: D
authors.lastname: Körholz
authors.forename: C M
authors.initials: CM
authors.lastname: Niemeyer
authors.forename: K
authors.initials: K
authors.lastname: Kabisch
authors.forename: N
authors.initials: N
authors.lastname: Graf
authors.forename: A
authors.initials: A
authors.lastname: Reiter
authors.forename: H
authors.initials: H
authors.lastname: Scheel-Walter
authors.forename: C
authors.initials: C
authors.lastname: Bender-Götze
authors.forename: W
authors.initials: W
authors.lastname: Behnisch
authors.forename: J
authors.initials: J
authors.lastname: Hermann
authors.forename: G
authors.initials: G
authors.lastname: Mann
authors.forename: J
authors.initials: J
authors.lastname: Ritter
authors.forename: M
authors.initials: M
authors.lastname: Zimmermann
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005858:Germany; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000009:adverse effects; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D015255:Idarubicin